TAK-875 (fasiglifam) is a GPR40 agonist which was developed for the treatment of type 2 diabetes. However, TAK-875 was withdrawn from phase III clinical trials due to drug-induced liver injury (DILI).
In this poster, we focus on:
investigating the mechanism behind the hepatotoxicity of TAK-875
an in-depth understanding of the effect of TAK-875 on mitochondrial toxicity
understanding the impact of plasma protein binding
Read our poster to learn more about our research!
Sounds interesting? Enter your details below to continue reading…
Join our community
Discover the exclusive benefits on offer if you join our community.